Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global AI in Pharma Market Report (2022 to 2031) – Featuring Novartis, Merck and GNS Healthcare Among Others

Published

on

Dublin, May 05, 2022 (GLOBE NEWSWIRE) — The “AI In Pharma Global Market Report 2022, By Technology, Drug Type, Application” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global ai in pharma market.

This report focuses on ai in pharma market which is experiencing strong growth. The report gives a guide to the ai in pharma market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Major players in the AI in pharma market are Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise Inc., Exscientia, Cyclica, NVIDIA Corporation, XtalPi Inc., BenevolentAI, Cloud Pharmaceuticals Inc, BERG LLC, Bayer, Pfizer, Recursion Pharmaceuticals Inc. and Bristol-Myers Squibb.

The global AI in pharma market is expected to grow from $934.56 million in 2021 to $1,236.09 million in 2022 at a compound annual growth rate (CAGR) of 32.3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2021. The market is expected to reach $3626.24 million in 2026 at a CAGR of 30.9%.

The artificial intelligence (AI) in pharma market consists of sales of AI in the pharma and related services that use an automated algorithm to perform tasks that traditionally rely on human intelligence. It can be useful in handling data and presenting results that encourage better decision-making and save human efforts, cost, and time. The market consists of revenue generated by artificial intelligence (AI) companies, which are applying in the pharmaceutical industry. Only goods and services traded between entities or sold to end consumers are included.

The main technology types of artificial intelligence (AI) in pharma are context-aware processing, natural language processing, querying method, deep learning. Natural language processing is a a branch of artificial intelligence (AI), concerned with giving computers the ability to understand text and spoken words in the same way that humans do. The various drugs produced are small molecule and large molecules that are used for diagnosis, clinical trial research, drug discovery, research and development and epidemic prediction.

North America was the largest region in the AI in pharma market in 2021. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on an average 10-15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs. For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startup Insilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in the pharma market.

Lack of skilled professionals may hamper the growth of artificial intelligence in the pharma market. In 2019, Indeed.com revealed that AI job postings increased 29.1% over the last year and yet, with no uncertainty due to the AI skills gap, searches for AI-related roles decreased by 14.5% over the same period. The shortage of AI skills is seen as a major barrier to the pace of technology’s adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in the pharma market.

Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in the pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization and process automation.

Key Topics Covered:

1. Executive Summary

2. AI in Pharma Market Characteristics

3. AI in Pharma Market Trends And Strategies

4. Impact Of COVID-19 On AI in Pharma

5. AI in Pharma Market Size And Growth
5.1. Global AI in Pharma Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global AI in Pharma Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. AI in Pharma Market Segmentation
6.1. Global AI in Pharma Market, Segmentation Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Context-Aware Processing
  • Natural Language Processing
  • Querying Method
  • Deep Learning

6.2. Global AI in Pharma Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Small Molecule
  • Large Molecules

6.3. Global AI in Pharma Market, Segmentation By Application:, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Diagnosis
  • Clinical Trial Research
  • Drug Discovery
  • Research and Development
  • Epidemic Prediction

7. AI in Pharma Market Regional And Country Analysis
7.1. Global AI in Pharma Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global AI in Pharma Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/d9jki7

Attachment


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

dsm-firmenich completes on-market repurchase of 500,000 shares to cover share plans

Published

on

dsm-firmenich-completes-on-market-repurchase-of-500,000-shares-to-cover-share-plans

KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, April 16, 2024 /PRNewswire/ — dsm-firmenich today announces that it has repurchased 500,000 ordinary shares in the period from April 8, 2024 up to and including April 12, 2024 at an average price of €103.29. This is in accordance with the on-market share repurchase program announced on April 8, 2024, covering commitments under the Group’s share-based compensation plans. This repurchase concludes the program to repurchase 500,000 shares for a total consideration of €51.6 million.

For more detailed information see ‘Daily transaction details On-Market Share Repurchase Program announced April 8, 2024’.
As announced on April 8, 2024, the on-market share repurchase program is followed by a repurchase of 1,000,000 shares by means of an equity forward transaction. The forward transaction is expected to be entered into in April 2024, and dsm-firmenich expects to take delivery of the shares in 2025.
For more information, please contact:
dsm-firmenich investor relations enquiries:Email: [email protected]
dsm-firmenich media enquiries:Email: [email protected]   
About dsm-firmenichAs innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people. www.dsm-firmenich.com 
Disclaimer
This press release does not constitute or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.This press release may contain forward-looking statements with respect to dsm-firmenich’s future. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of this press release prevails over other language versions.
Logo – https://mma.prnewswire.com/media/2071772/dsm_firmenich_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dsm-firmenich-completes-on-market-repurchase-of-500-000-shares-to-cover-share-plans-302116949.html

Continue Reading

Artificial Intelligence

Infosys drives hybrid cloud-powered innovation for Team Global Express

Published

on

infosys-drives-hybrid-cloud-powered-innovation-for-team-global-express

Infosys Cobalt accelerates the customer’s transition to the new environment, enabling them to deliver exceptional customer service
SYDNEY, April 16, 2024 /PRNewswire/ — Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, announced the successful completion of the technology landscape separation program of the Australian express logistics business, Team Global Express.

Infosys leveraged the established blueprints and tools from Infosys Cobalt to build on its strategic collaboration with Team Global Express and drive hybrid cloud-powered innovation. The team set up a greenfield technology environment and migrated Global Express’ applications and services to a world-leading sustainable and energy-efficient data centre and public cloud.
More than 300 applications were migrated to the new environment with zero business impact to its 4,000 plus users including applications and network integration of over 100 sites. The technology separation was completed on time without any operational impact for either of the organisations.
The program also involved modernising the overall technology landscape by embedding a cloud-first approach into its core business strategy to reduce the technical debt inherited from the parent organisation. As part of the migration, 70% of its applications were moved to the cloud, to gain from the technical benefits provided by the public cloud and create a secure and agile foundation for future digital transformation. The exercise helped reduce the overall risk by uplifting the base infrastructure and the security posture. It significantly improved the employee experience by reducing disruptions and improving operational productivity.
As the lead systems integrator, Infosys managed the program end-to-end, enabling Team Global Express’ transport and logistics business to deliver exceptional customer service. Infosys’ solution is a ‘Separate First and Transform Later’ strategy to align on-time separation without any impact ensuring operational stabilisation (operational journey transition from build to operate).
Infosys, with Team Global Express, won the 2024 ISG Paragon Award ANZ in gold category for this successful transformation program.
Danny Gravell, CIO of Team Global Express, said, “Our partnership with Infosys enabled us to successfully set up an independent technology capability and transform our foundation technology platforms. We value Infosys’ thought leadership, collaborative approach, and experience in implementing infrastructure and cloud transformation programs as a true strategic partner. By using the ready-to-use templates from Infosys Cobalt, we could complete the transformation at speed with maximum efficiency. This program has enabled us to work towards providing the best possible experience for our customers.”
Karmesh Vaswani, Executive Vice President & Global Head of Consumer, Retail & Logistics, Infosys, said, “The separation program for Team Global Express presented a unique opportunity to achieve significant value. This complex program challenged us to not only accomplish the separation on-time and without business disruption, but also seamlessly establish a modern, secure and scalable digital foundation to accelerate their future growth. Leveraging our proven Infosys Cobalt cloud ecosystem and through a collaborative partnership with Team Global Express, we successfully navigated the complexities of this program, achieving an outcome that ranks among our most impactful engagements in the Australia and New Zealand region.”
About Team Global Express
Team Global Express is a logistics solutions company backed by Allegro Funds, Australia’s most awarded transformation and turnaround private equity firm. With the most significant multimodal network in the country, Team Global Express operates aircraft, trucks, ships and rail across Australia and New Zealand, with flexible transport options and new product solutions to help our customers grow their business.
With a strong commitment to sustainability, Team Global Express is leading the way to become the most sustainable logistics operator and transform the sector, which includes conducting the largest trial of electric trucks in Australia.
About Infosys
Infosys is a global leader in next-generation digital services and consulting. Over 300,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. We enable clients in more than 56 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace.
Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.
Safe Harbor
Certain statements in this release concerning our future growth prospects, or our future financial or operating performance, are forward-looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, our ability to attract and retain personnel, our transition to hybrid work model, economic uncertainties, technological innovations such as Generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, our corporate actions including acquisitions, and cybersecurity matters. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2023. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.
Logo: https://mma.prnewswire.com/media/633365/Infosys_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/infosys-drives-hybrid-cloud-powered-innovation-for-team-global-express-302117537.html

Continue Reading

Artificial Intelligence

50 Scholarships Empowering STEM & Sustainability Education for UK Youth

Published

on

50-scholarships-empowering-stem-&-sustainability-education-for-uk-youth

NEW YORK, April 15, 2024 /PRNewswire/ — AFS Intercultural Programs, a global non-profit educational exchange organisation, is proud to announce the second year of Global STEM Innovators scholarships in the United Kingdom – equipping young people with access to STEM, sustainability, and global competence education.

The AFS Global STEM Innovators is a five-week, full-scholarship exchange program, for 50 youth (ages 14 to 17), that fosters the understanding and skills needed to help the world transition to a more sustainable future. The program combines an interactive virtual exchange focused on global skills, and a week-long, in-person workshop focused on innovations in STEM. Scholars will explore sustainability and social impact through diverse perspectives, innovations, and real-world case studies, including opportunities to meet with STEM industry leaders and experts.
Upon program completion, scholars earn the award-winning AFS Global Competence Certificate and are invited to join the AFS Global STEM alumni community, which offers mentorship, networking, and further academic and professional development opportunities.
Program Dates
Application Deadline: 15 May 2024Virtual Exchange: 8 July – 9 August 2024 (online)Workshop: 11-17 August 2024 (in-person)Eligibility
Legal residence in one of the following postcode areas: Aberdeen (AB), Cardiff (CF), Darlington (DL), Newport (NP), Swansea (SA), or Teesside (TS)Birthdate: 1 January 2007 – 31 July 2010AFS has partnered with Celtic English Academy in Wales to administer the program. Full scholarship funding is provided by bp, which supports AFS Global STEM programs to help build the STEM talent that the world needs to create sustainable solutions and improve the diversity of talent in STEM.
AFS brings decades of expertise in impact-driven educational exchange and the power of a global network. “We know that young people are eager to innovate and bring positive change to their communities, and we are proud to empower young people with critical global skills and knowledge, like cross-cultural communication, empathy, and conflict resolution,” says Daniel Obst, President & CEO of AFS. “Educating more young people to become global citizens is crucial to create a more sustainable future.”
To learn more or apply, please visit https://afs.org/global-stem/innovators/.
 
Photo – https://mma.prnewswire.com/media/2386290/AFS_Global_STEM_Innovators_UK.jpg
Logo – https://mma.prnewswire.com/media/1809272/AFS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/50-scholarships-empowering-stem–sustainability-education-for-uk-youth-302117146.html

Continue Reading

Trending